Get the Stockscreener App
25.26
3.02%
0.74
After Hours:
25.26
Jade Biosciences Inc stock is traded at $25.26, with a volume of 295.57K.
It is up +3.02% in the last 24 hours and up +63.07% over the past month.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
See More
Previous Close:
$24.52
Open:
$24.77
24h Volume:
295.57K
Relative Volume:
0.58
Market Cap:
$1.25B
Revenue:
-
Net Income/Loss:
$-91.76M
P/E Ratio:
-4.6314
EPS:
-5.4541
Net Cash Flow:
$-94.89M
1W Performance:
-4.50%
1M Performance:
+63.07%
6M Performance:
+163.13%
1Y Performance:
+119.65%
1-Day Range:
$24.15
$25.39
1-Week Range:
$22.09
$26.26
52-Week Range:
$6.565
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
(781) 312-3013
Address
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
25.26 | 1.21B | 0 | -91.76M | -94.89M | -5.4541 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
Jade Biosciences Reshapes Clinical Leadership As Valuation Debate Persists - Sahm
2 Small-Cap Stocks With Big Potential to Buy Under $30 - Barchart
Jade Biosciences (NASDAQ:JBIO) Stock Price Down 9.6%Here's What Happened - MarketBeat
What is HC Wainwright's Forecast for JBIO FY2030 Earnings? - MarketBeat
Jade Biosciences (NASDAQ: JBIO) outlines 2026 director votes, auditor and jury waiver - Stock Titan
Jade Biosciences (NASDAQ:JBIO) Sets New 1-Year HighHere's What Happened - MarketBeat
FY2028 Earnings Forecast for JBIO Issued By HC Wainwright - MarketBeat
Jade Biosciences stock hits 52-week high at 27.44 USD By Investing.com - Investing.com South Africa
Jade Biosciences (JBIO) price target increased by 10.24% to 28.82 - MSN
BlackRock (NYSE: JBIO) reports 2.3M JADE stake, 4.7% disclosed - Stock Titan
Jade Biosciences stock hits 52-week high at 27.44 USD - Investing.com
Jade Biosciences stock price target raised to $45 by H.C. Wainwright - Investing.com Canada
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $45 - Moomoo
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
A Look At Jade Biosciences (JBIO) Valuation After Its Recent Share Price Surge - Sahm
Jade Biosciences, Inc. (NASDAQ:JBIO) Short Interest Update - MarketBeat
Jade Biosciences, Inc. Grants Equity Award to New Chief Medical Officer Edward R. Conner, M.D. - Quiver Quantitative
New Jade medical chief gets 500,000 stock options at $25.38 - Stock Titan
Jade Biosciences Elevates Andrew King to R&D President - The Globe and Mail
Jade Biosciences names Edward Conner as chief medical officer By Investing.com - Investing.com Australia
Jade Biosciences (NASDAQ:JBIO) Shares Up 9.7%What's Next? - MarketBeat
Jade Biosciences names Edward Conner as chief medical officer - Investing.com
Jade Biosciences Appoints Andrew King as President of Research & Development – 8-K SEC Filing Update - Minichart
Jade Biosciences appoints Andrew King as president of research and development - Investing.com UK
Jade Biosciences appoints Andrew King as president of research and development By Investing.com - Investing.com South Africa
Jade Biosciences, Inc. Announces Executive Changes - marketscreener.com
Andrew King becomes President of R&D at Jade Biosciences (NASDAQ: JBIO) - Stock Titan
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer - The Manila Times
Jade brings in new CMO ahead of kidney disease trial and Phase 1 data - Stock Titan
We're Hopeful That Jade Biosciences (NASDAQ:JBIO) Will Use Its Cash Wisely - simplywall.st
We're Not Very Worried About Jade Biosciences' (NASDAQ:JBIO) Cash Burn Rate - Moomoo
Jade Biosciences: Caution Advised Before Clinical Trial Results (NASDAQ:JBIO) - Seeking Alpha
Jade Biosciences (JBIO) Stock Hits 52-Week High (+4.43%) 2026-04-18Bullish Pattern - Xã Thanh Hà
Jade Biosciences stock hits 52-week high at 23.23 USD By Investing.com - Investing.com India
Jade Biosciences (NASDAQ: JBIO) — director votes, auditor and jury‑waiver amendment - Stock Titan
Jade Biosciences stock hits 52-week high at 23.23 USD - Investing.com
Jade Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Jade Biosciences (NASDAQ:JBIO) Stock Price Up 9.7%Should You Buy? - MarketBeat
Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat
Jade Biosciences (JBIO) price target increased by 16.48% to 26.14 - MSN
Can Jade Biosciences (JBIO) Stock Maintain Growth | Price at $18.30, Up 2.29%Diversification - Newser
Volume Report: Is Jade Biosciences Inc a stock for growth or value investorsInsider Buying & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Aug Drivers: Is Jade Biosciences Inc a stock for growth or value investors2026 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
Jade Biosciences (NASDAQ:JBIO) Rating Increased to Hold at Zacks Research - MarketBeat
Jade Biosciences (NASDAQ:JBIO) Trading Up 7.9%What's Next? - MarketBeat
867,284 Shares in Jade Biosciences, Inc. $JBIO Bought by Aberdeen Group plc - Defense World
Jade Biosciences Inc Stock (JBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):